Abstract
The classification system for vascular anomalies now used by experts worldwide comprises two distinct disease entities that differ in their biologic and pathologic features: vascular tumors and vascular malformations. Vascular tumors include infantile and congenital hemangiomas, tufted angiomas, and kaposiform hemangioendotheliomas. Infantile hemangiomas, the most common vascular anomaly, generally have a predetermined life cycle (proliferation and subsequent involution). GLUT-1, a glucose transporter, is a marker for these specific lesions during all phases of development. Vascular malformations are classified according to their vascular tissue of origin and include capillary, venous, arteriovenous, lymphatic, and mixed malformations. Complex lymphatic malformations and complex mixed malformations, which may have most vascular components, are the most difficult vascular malformations to successfully treat. These lesions are present at birth and often expand or grow in response to trauma, infection, or hormonal changes. Imaging advancements have enabled more accurate assessments and improved management of vascular anomalies. In addition, many lesions are now being managed with targeted pharmacologic therapy. Propranolol and steroids are used for complex or disfiguring tumors, and new anti-angiogenesis inhibitors such as sirolimus are selectively used to treat lymphatic and venous lymphatic malformations that are poorly responsive to sclerotherapy, embolization, and surgical excision. Multimodal therapies are often essential for complex lesions and require the combined expertise of an interdisciplinary team.
Similar content being viewed by others
References
Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69:412–422
North PE, Waner M, Mizeracki AM et al (2001) A unique microvascular phenotype shared by juvenile and human placenta. Arch Dermatol 137:559–570
Adams DM, Lucky AW (2006) Cervicofacial vascular anomalies. I. Hemangiomas and other benign vascular tumors. Sem Ped Surg 15:124–132
Hemangioma Investigator Group, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL et al (2007) Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 150:291–294
Bauland CG, Smit JM, Bartelink LR, Zondervan HA, Spauwen PH (2010) Hemangioma in the newborn: increased incidence after chorionic villus sampling. Prenat Diagn 30:913–917
Phung TL, Hockman M, Mihm MC (2005) Current knowledge of the pathogenesis of infantile hemangiomas. Arch Facial Plast Surg 7:319–321
Bischoff J (2009) Projenitor cells in infantile hemangioma. J Craniofac Surg 20:695–697
Barnés CM, Christison-Lagay EA, Folkman J (2007) The placenta theory and the origin of infantile hemangioma. Lymphatic Res Biol 5:245–255
Fishman SJ, Mulliken JB (1998) Vascular anomalies: a primer for pediatricians. Pediatr Clin North Am 45:1455–1477
Drolet B, Esterly N, Frieden IJ (1999) Hemangiomas in children. N Engl J Med 341:173–181
Mulliken JB, Enjolras O (2004) Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 50:875–882
North PE, Waner M, James CA, Mizeracki A et al (2001) Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch Dermatol 137:1607–1620
Donaldson JS (2008) Pediatric vascular anomalies: the role of imaging and interventional radiology. Pediatr Ann 37:414–424
Frieden IJ, Rogers M, Garzon MC (2009) Conditions masquerading as infantile haemangioma: part 1. Australas J Dermatol 50:77–99
Frieden IJ, Rogers M, Garzon MC (2009) Conditions masquerading as infantile haemangioma: part 2. Australas J Dermatol 50:153–170
Léauté-Labrèze C, Prey S, Ezzedine K (2011) Infantile haemangioma: part II. Risks, complications and treatment. J Eur Acad Dermatol Venereol 25:1254–1260
Horii KA, Drolet BA, Frieden IJ, Baselga E et al (2011) Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol 28:245–253
Metry DW, Haggstrom An, Drolet BA, Baselga E et al (2006) A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. A J Med Genet Part A 140A:975–986
Drolet BA, Chamlin SL, Garzon MC, Adams D et al (2010) Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatry 157:789–794
Christison-Lagay ER, Burrows PE, Alomari A et al (2007) Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatry Surg 42:62–68
Dickie B, Dasgupta R, Nair R, Alonso MH et al (2009) Spectrum of hepatic hemangiomas: management and outcome. J Pediatry Surg 44:125–133
Huang SA, Tu HM, Harney JW et al (2000) Vascular anomalies. Curr Probl Surg 37:517–584
Orlow SJ, Isakoff MS, Blei F (1997) Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. J Pediatry 131:643–646
Kushner B (1990) Infantile orbital hemangiomas. Int Pediatry 5:249–257
Hynes S, Narasimhan K, Courtemanche DJ, Arneja JS (2013) Complicated infantile hemangioma of the lip: outcomes of early versus late resection. Plast Reconstr Surg 131:373e–379e
Azizkhan RG (2007) Vascular anomalies of childhood. In: Fischer JE, Bland KI et al (eds) Master of surgery. 5th edn. Lippincott Williams & Wilkins, Philadelphia, p 28
Marqueling AL, Oza V, Frieden IJ, Puttgen KB (2013) Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol 30:182–191
Storch CH, Hoeger PH (2010) Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Brit J Dermatol 163:269–274
Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y et al (2010) Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope 120:676–681
Mulliken JB, Rogers GF, Marler JJ (2002) Circular excision of hemangioma and purse-string closure: the smallest possible scar. Plast Reconstr Surg 109:1544–1554
Huang SA, Tu HM, Harney JW et al (2000) Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343:185–189
Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE (1997) Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 100:1377–1386
Lyons LL, North PE, Mac-Moune LF, Stoler MH et al (2004) Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 28:559–568
Haisley-Royster C, Enjolras O, Frieden IJ et al (2002) Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 24:459–462
Kelly M (2010) Kasabach-Merritt phenomenon. Pediatr Clin N Am 57:1085–1089
Hammill AM, Wentzel MS, Gupta A, Nelson S et al (2011) Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 57:1018–1024
Maguiness SM, Liang MG (2011) Management of capillary malformations. Clin Plastic Surg 38:65–73
Garzon MC, Huang JT, Enjolras O, Frieden IJ (2007) Vascular malformations. Part II: associated syndromes. J Am Acad Dermatol 56:541–564
Comi AM (2011) Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome. The neurologist 17:179–184
Wooderchak-Donahue W, Stevenson DA, McDonald J, Grimmer JF et al (2012) RASA1 analysis: clinical and molecular findings in a series of consecutive cases. Eur J Med Genet 55:91–95
Comi AM (2007) Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol 5:257–264
Vikkula M, Boon LM, Carraway KL et al (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87:1181–1190
Rodriguez-Manero M, Aguado L, Redondo P (2010) Pulmonary arterial hypertension in patients with slow-flow vascular malformations. Arch Dermatol 146:1347–1352
Greene AK, Alomari AI (2011) Management of venous malformations. Clin Pastic Surg 38:83–93
Yamaki T, Nozaki M, Sakurai H, Takeuchi M et al (2008) Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations. J Vasc Surg 47:578–584
Dompmartin A, Vikkula M, Boon LM (2010) Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology 25:224–235
Blei F (2008) Congenital lymphatic malformations. Ann N Y Acad Sci 1131:185–194
Marler JJ, Fishman SJ, Upton J, Burrows PE et al (2002) Prenatal diagnosis of vascular anomalies. J Pediatr Surg 37:318–326
Azizkhan RG, Rutter JM, Cotton RT et al (2006) Lymphatic malformations of the tongue base. J Pediatr Surg 41:1279–1284
Burrows PE, Mitri RK, Alomari A, Padua HM et al (2008) Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol 6:209–216
Poldervaart MT, Breugem CC, Speleman L, Pasmans S (2009) Treatment of lymphatic malformations with OK-432 (Picibanil): review of the literature. J Craniofac Surg 20:1159–1162
Mathur NN, Rana I, Bothra R et al (2005) Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol 69:75–80
Smith MC, Zimmerman MB, Burke DK, Bauman NM et al (2009) Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 119:107–115
Hassan Y, Osman AK, Altyeb A (2013) Noninvasive management of hemangioma and vascular malformation using intralesional bleomycin injection. Ann Plast Surg 70:70–73
Cuervo JL, Galli E, Eisele G, Johannes E et al (2011) Lymphatic malformations: percutaneous treatment with bleomycin. Arch Argent Pediatry 109:417–422
Tan WH, Baris HN, Burrows PE, Robson CD et al (2007) The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 44:594–602
Greene AK, Orbach DB (2011) Management of arteriovenous malformations. Clin Plastic Surg 38:95–106
Mounayer C, Hammami N, Piotin M et al (2007) Nidal embolization of brain arteriovenous malformations using Onyx in 94 patients. Am J Neuroradiol 28:518–523
Kulungowski AM, Fishman SJ (2011) Management of combined vascular malformations. Clin Plastic Surg 38:107–120
Jacob AG, Driscoll DJ, Shaughnessy WJ et al (1998) Klippel-Trenaunay syndrome: spectrum and management. Mayo Clin Proc 73:28–36
Rockson SG (2001) Lymphedema. Rev Am J Med 110:288–295
Nitecki S, Bass A (2007) Ultrasound-guided foam sclerotherapy in patients with Klippel-Trenaunay syndrome. Isr Med ASsoc J 9:72–75
Revencu N, Boon LM, Mulliken JB, Enjolras O et al (2008) Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA 1 mutations. Hum Mutat 29:959–65
Alomari AI (2009) Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol 18:1–7
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Azizkhan, R.G. Complex vascular anomalies. Pediatr Surg Int 29, 1023–1038 (2013). https://doi.org/10.1007/s00383-013-3393-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00383-013-3393-6